Caitong International Asset Management’s ImmuCell ICCC Stock Holding History

Caitong International Asset Management’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50	Buy	+5	New	+$44	﹤0.01%	2351

Other funds holding ICCC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Caitong International Asset Management's ICCC Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in ImmuCell (ICCC) in Q2 2026: 5 shares worth $50. The stake represents ﹤0.01% of the portfolio and ranks #2351 among its holdings.

31 funds tracked by Wall St. Rank hold ICCC as of Q2 2026.

Caitong International Asset Management held 5 shares of ImmuCell worth $50 as of Q2 2026.
ImmuCell was a new Caitong International Asset Management position in Q2 2026.
ImmuCell made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2351 holding.
31 funds tracked by Wall St. Rank held ImmuCell as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.